Chinese medicinal composition for immunoregulation of chronic hepatitis B in inactive phase or carrier state

Abstract

The invention discloses a Chinese medicinal composition for the immunoregulation of chronic hepatitis B in an inactive phase or a carrier state. The Chinese medicinal composition consists of the following medicaments in part by weight: 15 to 30 parts of astragalus, 10 to 15 parts of largehead atractylodes rhizome, 10 to 15 parts of epimedium herb, 10 to 15 parts of glossy privet fruit, 10 to 15 parts of south dodder seed, 10 to 15 parts of Chinese magnoliavine fruit, 10 to 15 parts of medlar, 15 to 30 parts of red sage root, 15 to 30 parts of turtle shell, 15 to 60 parts of underleaf pearl, 10 to 15 parts of buffalo horn, and 10 to 30 parts of Chinese honeylocust spine. The Chinese medicinal composition is applicable to the immunoregulation therapy of the CHB in the inactive phase or a low (non) replicative phase and the carrier state, is expected to mainly strengthen body resistance and also clear residual pathogenic factors, has the effects of replenishing qi, tonifying kidney, dissolving blood stasis and releasing toxin, and can well consolidate and maintain the treatment effect of clinical inactive CHB patients and HBV (hepatitis B virus) carriers in an immune tolerant phase and an immune active phase of CHB .

Description

technical field [0001] The invention relates to a traditional Chinese medicine combination medicine for immune regulation of chronic hepatitis B in the inactive phase or in the carrier state. Background technique [0002] Chronic hepatitis B (CHB) is one of the most common diseases in the world and the ninth leading cause of human death worldwide. my country is an area with a high incidence of hepatitis B virus (HBV) infection. According to the national hepatitis B epidemiological survey carried out in 2006, the carrier rate of hepatitis B surface antigen (HBsAg) in the Chinese population is 7.18%, and there are still HBsAg carriers About 93 million people, about 30 million CHB patients, 10-30% of them can develop into liver cirrhosis, some patients can develop into liver cancer, and nearly 500,000 people die from liver disease every year in the whole country. Chronic hepatitis B has caused huge losses to patients, families, society, economy and environment. At present, the...

AI Technical Summary

Problems solved by technology

At present, the curative effect of Chinese and Western medicines on this disease is not good, and the expectations of doctors and patients for the treatment of chronic hepatitis B have not been realized, especially for the treatment of immune regulation in the inactive stage of chronic hepatitis B, there is no practical and effective drug